We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.

Video Block

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iustLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam.

Quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure

Case study 1

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex e magna aliquam erat volutpat. Ut wisi enim ad minim veniam.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna.

Call to action

Case study 2

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex e magna aliquam erat volutpat. Ut wisi enim ad minim veniam.

Call to action

Case study 3

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex e magna aliquam erat volutpat. Ut wisi enim ad minim veniam.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex e magna aliquam erat volutpat. Ut wisi enim ad minim veniam.

Call to action

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Exerci tation ullamcorper suscipit lobortis Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex e magna aliquam erat volutpat. Ut wisi enim ad minim veniam

This quote is from

Name

phone

email

Charles Spicer

Non-Executive Chairman

Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors.

He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.

Guilio Cerroni

Chief Executive Officer

Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC Ltd to global investment firm, KKR & Co. Inc.

Susan Lowther

Chief Financial Officer and Company Secretary

Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 Ltd prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc and Finance Director of RiboTargets Limited until its acquisition by Vernalis plc.

The following information is disclosed in accordance with AIM Rule 26:

Business description Please see our About Us page for details.
Directors name and biographies Information about our directors can be found on our IXICO board page.
Corporate governance Please see our Governance page for details.
Country of incorporation and main country of operation Country of incorporation: England and Wales
Company registration number: 03131723
Main country of operation: United Kingdom
UK City Code on Takeovers and Mergers The Company is subject to the UK City Code on Takeovers and Mergers.
Constitutional document Articles of Association can be found on our Company Documents page.
Details of any other exchanges or trading platforms The Company has not applied or agreed to have any of it securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.
Number of securities in issue, noting any held as treasury shares Securities in issue: Please see our Share Price page for details.
Treasury shares: The Company does not hold any Ordinary Shares in treasury.
The identity and percentage holding of significant shareholders Please see our Shareholder Information page for details.
Details of any restrictions on the transfer of securities There are no restrictions on the transfer of securities.
Annual and interim financial reports All relevant documents can be found on our Company Documents page.
Regulatory news Regulatory news announcements can be found on our RNS Announcements page.
AIM Admission document and circulars All relevant documents can be found on our Company Documents page.
Advisers Please see our Contacts & Advisers page for more information.

Content updated 27 October 2018